Skip to main content

Chronic Myeloid Leukemia

  • Book
  • © 2021

Overview

  • Presents state-of-the-art reviews of key issues relating to chronic myeloid leukemia
  • Covers a wide range of management topics
  • Discusses prognostic aspects and early response prediction
  • Examines the changing face and cost of care

Part of the book series: Hematologic Malignancies (HEMATOLOGIC)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (16 chapters)

Keywords

About this book

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. 


Editors and Affiliations

  • ELN Foundation, Weinheim, Germany

    RĂ¼diger Hehlmann

About the editor

RĂ¼diger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany.

Founder and Chair, European LeukemiaNet (ELN)

Founder and chair of the German CML Study Group 1982-2017

Former Secretary General

International Association of Comparative Research on Leukemia & Related Diseases (IACRLRD)

Former Chief of Medicine, Dean & President

German Society of Hematology and Oncology

Honorary member of the Polish and German Societies for Hematology and Oncology

Current focus: promotion of cooperative research for curing leukemia


Bibliographic Information

  • Book Title: Chronic Myeloid Leukemia

  • Editors: RĂ¼diger Hehlmann

  • Series Title: Hematologic Malignancies

  • DOI: https://doi.org/10.1007/978-3-030-71913-5

  • Publisher: Springer Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021

  • Hardcover ISBN: 978-3-030-71912-8Published: 03 June 2021

  • Softcover ISBN: 978-3-030-71915-9Published: 04 June 2022

  • eBook ISBN: 978-3-030-71913-5Published: 02 June 2021

  • Series ISSN: 2197-9766

  • Series E-ISSN: 2197-9774

  • Edition Number: 2

  • Number of Pages: IX, 273

  • Number of Illustrations: 7 b/w illustrations, 35 illustrations in colour

  • Topics: Oncology, Hematology

Publish with us